Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

Sponsor

Albert Einstein College of Medicine (Other)

Overall Status

Withdrawn

CT.gov ID

NCT02507076

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arm

Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This pilot clinical trial studies isolated limb perfusion with melphalan in treating patients with stage IIIB-IV melanoma or sarcoma. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating a chemotherapy solution and infusing it directly into the arteries around the tumor may kill more tumor cells.

Condition or Disease	Intervention/Treatment	Phase
Basal Cell Carcinoma of the Skin Eccrine Carcinoma of the Skin Recurrent Adult Soft Tissue Sarcoma Recurrent Melanoma Recurrent Skin Cancer Squamous Cell Carcinoma of the Skin Stage III Adult Soft Tissue Sarcoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Adult Soft Tissue Sarcoma Stage IV Melanoma	Drug: isolated limb perfusion Drug: melphalan Procedure: quality-of-life assessment	N/A

Detailed Description

PRIMARY OBJECTIVES:

This prospective trial will evaluate total response rate, including complete and partial response, in patients with unresectable extremity melanoma (or other skin cancer including but not limited to Merkel cell carcinoma) or soft tissue sarcoma treated with hyperthermic-isolated limb perfusion (ILP) with melphalan.

SECONDARY OBJECTIVES:

To evaluate the technical parameters including achievement of regional hyperthermia, arterial blood gas (ABG), tourniquet time, and their association with tumor response.
To evaluate time to recurrence and progression free survival (PFS) for patients with advanced extremity melanoma or sarcoma who achieved complete response after treatment with ILP with melphalan.
To evaluate overall survival rate and duration of survival for patients with advanced melanoma or sarcoma limited to extremity undergoing ILP with melphalan.
To assess quality of life (QOL) score for patients undergoing ILP with melphalan.

OUTLINE:

Patients undergo ILP with melphalan intravenously (IV) over 60 minutes.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 4 months for 1 year, and then periodically thereafter.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases

Study Start Date :

Apr 1, 2012

Actual Primary Completion Date :

Jul 1, 2014

Actual Study Completion Date :

Jul 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (ILP with melphalan) Patients undergo ILP with melphalan IV over 60 minutes.	Drug: isolated limb perfusion Undergo ILP with melphalan Other Names: isolated limb infusion Drug: melphalan Undergo ILP with melphalan Other Names: Alkeran CB-3025 L-PAM L-phenylalanine mustard L-Sarcolysin Procedure: quality-of-life assessment Ancillary studies Other Names: quality of life assessment

Arm

Intervention/Treatment

Experimental: Treatment (ILP with melphalan)

Patients undergo ILP with melphalan IV over 60 minutes.

Drug: isolated limb perfusion

Undergo ILP with melphalan

Other Names:

isolated limb infusion

Drug: melphalan

Undergo ILP with melphalan

Other Names:

Alkeran

CB-3025

L-PAM

L-phenylalanine mustard

L-Sarcolysin

Procedure: quality-of-life assessment

Ancillary studies

Other Names:

quality of life assessment

Outcome Measures

Primary Outcome Measures

Overall response rate (complete and partial response) assessed by the RECIST v1.1 [Up to 12 weeks]
Rates of complete and partial response will be computed and reported with their 95% confidence intervals.

Secondary Outcome Measures

Time to recurrence [Up to 4 years]
Kaplan-Meier methods will be used. 95% confidence intervals will be computed using Greenwood's formula.
Progression-free survival [Time of ILP procedure to date of recurrence, assessed up to 4 years]
Kaplan-Meier methods will be used. 95% confidence intervals will be computed using Greenwood's formula.
Overall survival [Time of ILP treatment to time of death, assessed up to 4 years]
Kaplan-Meier methods will be used. 95% confidence intervals will be computed using Greenwood's formula.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
The patient must have histological-proven primary or recurrent extremity melanoma (or other skin cancer including but not limited to Merkel cell carcinoma) or sarcoma, stage IIIB, IIIC, or IV (American Joint Committee on Cancer [AJCC] staging must be documented in patient's medical record, as determined by computed tomography [CT] of the chest, abdomen and pelvis, and/or whole body positron emission tomography [PET] scan, within six weeks prior to administration of study drug)
Patients with stage IV disease who have high tumor burden and extensive symptomatic extremity disease
Patients with stage IIIC disease must either have had regional lymph nodes previously removed or will have them removed either at the time of regional treatment or soon thereafter
Disease to be treated by ILP must be unresectable and distal to the planned site of tourniquet placement (which for the leg is generally the apex of the femoral triangle, or for the arm is distal to the deltoid insertion)
Patient's disease must be bi-dimensionally measurable by caliper or radiological method as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (RECIST updated version 1.1); lesional tissue not necessary for diagnostic or other clinical purposes may be designated prospectively for research tissue banking
Hemoglobin >= 8.0 g/dl
White blood count (WBC) of >= 2000 m^3
Absolute neutrophil count (ANC) >= 1,500/mm^3
Platelet count >= 100,000/mm^3
Total bilirubin =< 1.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x the ULN
Creatinine =< 1.5 x ULN
Patient must have a palpable femoral/radial pulse in the affected extremity
Patients must have a life expectancy of > 6 months
Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study-related procedures
Patient or the patient's legally acceptable representative must provide written authorization to allow the use and disclosure of their protected health information at any institution subject to United States Health Insurance Portability and Accountability Act (US HIPAA) regulations; NOTE: This may be obtained in either the study-specific informed consent or in a separate authorization form and must be obtained from the patient prior to study registration

Exclusion Criteria:

Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (angina symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
Known brain metastasis; patients with neurological symptoms must undergo a CT scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Active clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Pulmonary hemorrhage/bleeding event >= CTCAE grade 2 within 4 weeks of ILP/isolated limb infusion (ILI); any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks ILP/ILI
Major surgery or significant traumatic injury within 30 days of ILI/ILP
Evidence or history of bleeding diathesis or coagulopathy
Antineoplastic therapy, radiotherapy, or any other investigational drug within 30 days prior to first study drug administration
Patients with symptoms or signs of vascular insufficiency; specifically, patients with any history of blood clots or lifestyle altering ischemic peripheral vascular disease will be excluded
History of allergic reactions and/or hypersensitivity to melphalan
Psychiatric conditions or diminished capacity that could compromise the giving of informed consent, or interfere with study compliance
Pregnant or nursing women are not eligible for this study
Unable to return at the regular required intervals for reassessment, or study drug administration
Patients with known heparin induced thrombocytopenia